Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 1/20 | 0.56 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.56 |
| ▸ | EGFR | P00533 | 17/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408920 | 1.00 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL31026187 | 0.76 | EGFR (0.49) | EGFR | |
| SCHEMBL6484704 | 0.76 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL1368716 | 0.76 | SELE (0.61) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL1192721 | 0.76 | EGFR (0.49) | EGFRMEN1 | |
| SCHEMBL4388091 | 0.76 | SELE (0.70) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL3980685 | 0.72 | SELE (0.51) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL15628663 | 0.72 | SELE (0.56) | SELEVCAM1HDAC3HDAC1HDAC6 | |
| SCHEMBL439142 | 0.72 | SELE (0.56) | SELEVCAM1EGFRHDAC3HDAC1 | |
| SCHEMBL10325118 | 0.72 | SELE (0.51) | SELEVCAM1EGFRHDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2026-01-20 | — | — | US | disclosed |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-11-06 | — | — | US | disclosed |
| EP-4532495-A1 | CD73 INHIBITOR COMPOUNDS | Adorx therapeutics Limited (GB) | 2025-04-09 | — | — | EP | disclosed |
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | VANDERBILT UNIVERSITY | 2025-01-16 | — | — | US | disclosed |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ARRAY BIOPHARMA INC. (US) | 2024-12-24 | — | — | US | disclosed |
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | VIBLIOME THERAPEUTICS, LLC | 2024-12-05 | — | — | US | disclosed |
| US-20240293412-A1 | NAMPT ACTIVATORS FOR TREATING METABOLIC AND NEUROLOGICAL DISORDERS | UNIV ILLINOIS (US) | 2024-09-05 | — | — | US | disclosed |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-08-13 | — | — | US | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| EP-3892278-B1 | CYCLOALKANE-1,3-DIAMINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2024-02-28 | — | — | EP | disclosed |
| US-20050026935-A1 | Compounds | XENTION DISCOVERY LTD. | 2005-02-03 | — | — | US | disclosed |
| WO-2005007083-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-01-13 | — | — | US | disclosed |
| WO-2004112714-A2 | CHEMICAL COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004111057-A1 | THIENOPYRIMIDINE DERIVATIVES AS POTASSIUM CHANNEL INHIBITORS | XENTION DISCOVERY LIMITED (GB) | 2004-12-23 | — | — | WO | disclosed |
| EP-1463507-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SmithKline Beecham Corporation (US) | 2004-10-06 | — | — | EP | disclosed |
| WO-2004066921-A2 | ERBB4 CO-CRYSTAL | SMITHKLINE BEECHAM CORPORATION (US) | 2004-08-12 | — | — | WO | disclosed |
| WO-2003053446-A1 | THIENOPYRIMIDINE COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-07-03 | — | — | WO | disclosed |
| US-4196207-A | Process for controlling eradicating or preventing infestations of animals by Ixodid ticks | ICI AUSTRALIA LIMITED | 1980-04-01 | — | — | US | disclosed |
| US-4146716-A | PLANT GROWTH REGULATORS, FUNGICIDES, BACTERICIDES, VIRICIDES, INSECTICIDES | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400577-A1 | MODULATORS OF PROTEIN KINASES | MAP3K20, PRKCE, PRKCH | SELE 4017/4885VCAM1 2577/4885EGFR 862/4885 |
| US-20240293412-A1 | NAMPT ACTIVATORS FOR TREATING METABOLIC AND NEUROLOGICAL DISORDERS | NAMPT, NQO1, NADK | SELE 3018/4885VCAM1 3204/4885EGFR 4356/4885 |
| US-20050009845-A1 | Thienopyrimidine compounds as protein tyrosine kinase inhibitors | ERBB2, ERBB4, ERBB3 | SELE 4102/4885VCAM1 4288/4885EGFR 20/4885 |
| US-20250340565-A1 | CD73 INHIBITOR COMPOUNDS | ENTPD5, ENTPD1, NT5E | SELE 1862/4885VCAM1 2389/4885EGFR 1619/4885 |
| US-12060365-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MEN1, MLLT3 | SELE 2272/4885VCAM1 1454/4885EGFR 4052/4885 |
| US-20050026935-A1 | Compounds | KCNJ11, KCNJ1, KCNH1 | SELE 3568/4885VCAM1 2334/4885EGFR 4627/4885 |
| US-12171739-B2 | N4-phenyl-quinazoline-4-amine derivatives and related compounds as ErbB type I receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases | ERBB4, ERBB2, ERBB3 | SELE 1889/4885VCAM1 1927/4885EGFR 4/4885 |
| US-20250017935-A1 | 7,8-DIHYDRO-5H-1,6-NAPHTHYRIDINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | CHRM5, CHRM4, CHRM1 | SELE 4602/4885VCAM1 3177/4885EGFR 2426/4885 |
| US-12528822-B2 | Cycloalkane-1,3-diamine derivative | MLLT1, MLLT3, PRMT6 | SELE 3967/4885VCAM1 1044/4885EGFR 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.